This finding implies that detection of PRSS3 expression can be a useful prognosis marker and the targeting of PRSS3 can potentially represent a new strategy for invasive ductal carcinoma of the breast treatment. The gene discussed is PRSS3; the disease is invasive ductal breast carcinoma.